Open Access Review Paper
Semaglutide (Ozempic) and obesity. A comprehensive guide for aestheticians
Vasiliki Sofia Grech1
, Kleomenis Lotsaris2, Ioanna Grech3, Vasiliki Kefala3, Efstathios Rallis3
1Medical Doctor, Department of Care and Social Services, Healthcare Services, University of West Attica, Greece2Medical Doctor, Resident Psychiatrist in Psychiatry Department of General Hospital of Athens “Evaggelismos”
3Department of Biomedical Sciences. School of Health Professions. University of West Attica. Campus 1. Athens Greece
Download PDF
Published: 17 February 2024; https://doi.org/10.61873/RJDB1796
Abstract
Obesity is a complex interplay of biological, genetic, behavioural, and environmental factors. Going beyond the conventional Body Mass Index (BMI) evaluation, the complex relationship between obesity and skin diseases unveils the evolving role of aesthetics in health promotion. Adipose tissue, traditionally seen as an energy reservoir, is unveiled as a dynamic endocrine organ, playing a crucial role in the pathophysiological mechanisms of insulin resistance and metabolic syndrome. This article navigates the skin-deep impact of obesity and unravelling its influence on dermatological challenges. From disrupted epidermal barriers to diseases such as psoriasis and hidradenitis suppurativa, it further explores how licensed cosmetologists emerge as health advocates. For what is more, semaglutide, a ground-breaking GLP-1 agonist, takes the spotlight, tracing its journey from FDA approval for type 2 diabetes to its recent endorsement for obesity. The article examines its mechanism, efficacy, and unintended consequences of popularity, emphasizing the need for responsible medication use.
Keywords: obesity, skin, aesthetician, semaglutide
Please cite as:
Grech V.S., Lotsaris K., Grech I., Kefala V., Rallis E. Semaglutide (Ozempic) and obesity. A comprehensive guide for aestheticians. Rev. Clin. Pharmacol. Pharmacokinet. Int. Ed. 38(Sup1):31-35 (2024).